RxDoctor Payments Data

David Chalk, MD

Family Medicine · Anniston, ALNPI 1134106800

Payments from drug & device makers

$9,581in general payments, 2019–2025

Across 570 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Melinta Therapeutics, LLC$1K
  • Merck$952
  • Paratek Pharmaceuticals, Inc.$754
  • AbbVie$735
  • Bayer$648
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$9,580100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,581 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$166,585
Medicare patients
325
Services billed
2,225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide148$168,001
EliquisApixaban158$151,500
MounjaroTirzepatide83$88,183
FarxigaDapagliflozin Propanediol39$39,277
JanuviaSitagliptin Phosphate34$38,637
JardianceEmpagliflozin28$35,201
Tresiba Flextouch U-200Insulin Degludec27$30,800
LinzessLinaclotide20$26,483
TrulicityDulaglutide23$25,732
Tresiba Flextouch U-100Insulin Degludec42$25,510
XareltoRivaroxaban18$24,400
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$21,706
MyrbetriqMirabegron13$16,909
KerendiaFinerenone12$14,055
SantylCollagenase Clostridium Hist.12$12,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,436$168,001148 claims
PfizerEliquis$375$151,500158 claims
Lilly USA, LLCMounjaro, Trulicity$324$113,915106 claims
AstraZenecaFarxiga, Breztri Aerosphere$413$60,98366 claims
MerckJanuvia, Dulera$952$44,61146 claims
Boehringer IngelheimJardiance$420$35,20128 claims
AbbVieLinzess$735$26,48320 claims
Johnson & JohnsonXarelto$204$24,40018 claims
Astellas Pharma US IncMyrbetriq$51$16,90913 claims
BayerKerendia$648$14,05512 claims
Smith+NephewSantyl$57$12,08912 claims
Otsuka America Pharmaceutical, Inc.Rexulti$126$10,94115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Anniston

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →